Účtovná hodnota akcie spoločnosti IMV

Aká je hodnota metriky Účtovná hodnota akcie spoločnosti IMV?

Hodnota metriky Účtovná hodnota akcie spoločnosti IMV, Inc. je -0.40

Aká je definícia metriky Účtovná hodnota akcie?

Účtovná hodnota akcie (Book/Share) sa rovná majetku spoločnosti mínus záväzky spoločnosti podelené počtom vydaných akcií.

The book value of a company is the value of its assets according to its balance sheet account balance. For assets, the value is based on the original cost of the asset less any depreciation, amortization or impairment costs made against the asset. Traditionally, a company's book value is its total assets minus intangible assets and liabilities. However, in practice, depending on the source of the calculation, book value may variably include goodwill, intangible assets, or both. The value inherent in its workforce, part of the intellectual capital of a company, is always ignored. The book value of a company may be also referred as with the term net asset value.

The book value per share is the the balance sheet equity value divided by the number of shares outstanding at the date of the balance sheet. Book value per share can be used to generate a measure of comprehensive earnings, when the opening and closing values are reconciled. The sale of shares/units by a business increases the total book value. Book value per share will increase if the additional shares are issued at a price higher than the pre-existing book value per share. The purchase of its own shares by a business will decrease total book value. Book value per share will decrease if more is paid for them than was received when originally issued. Dividends paid out will decrease book value per share value.

Čomu sa venuje spoločnosť IMV?

IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and microsatellite instability high tumors, as well as in Phase I clinical trial for breast cancer. It also develops DPX-SurMAGE that is in Phase I clinical trial for bladder cancer; and DPX-COVID-19 and DPX-RSV for infectious diseases. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.

Firmy s metrikou účtovná hodnota akcie podobnou spoločnosti IMV

  • Hodnota metriky Účtovná hodnota akcie spoločnosti MediaAlpha je -0.40
  • Hodnota metriky Účtovná hodnota akcie spoločnosti Conyers Park Acquisition je -0.40
  • Hodnota metriky Účtovná hodnota akcie spoločnosti Sino International je -0.40
  • Hodnota metriky Účtovná hodnota akcie spoločnosti Sports Ventures Acquisition je -0.40
  • Hodnota metriky Účtovná hodnota akcie spoločnosti SearchGuy.com je -0.40
  • Hodnota metriky Účtovná hodnota akcie spoločnosti Molecular Data Inc je -0.40
  • Hodnota metriky Účtovná hodnota akcie spoločnosti IMV je -0.40
  • Hodnota metriky Účtovná hodnota akcie spoločnosti Inventiva S.A je -0.40
  • Hodnota metriky Účtovná hodnota akcie spoločnosti OptiNose Inc je -0.39
  • Hodnota metriky Účtovná hodnota akcie spoločnosti Venus Concept je -0.39
  • Hodnota metriky Účtovná hodnota akcie spoločnosti ParkerVision je -0.39
  • Hodnota metriky Účtovná hodnota akcie spoločnosti Hua Lien International () je -0.39
  • Hodnota metriky Účtovná hodnota akcie spoločnosti Phunware Inc je -0.39